EVIDENCE LIBRARY
Serotonin-Syndrome Case Included Triazolam but Focused on a New Antidepressant Addition
A chronic-pain case included triazolam in the medication history, but the authors’ serotonin-syndrome explanation centered on overlapping serotonergic drugs after amitriptyline was added.
A chronic-pain case included triazolam in the medication history, but the authors’ serotonin-syndrome explanation centered on overlapping serotonergic drugs after amitriptyline was added.
The chronology behind the diagnosis
Boudier-Revéret and Chang described a woman treated with several medications for chronic pain, including tramadol, duloxetine, pregabalin, acetaminophen, and triazolam. She developed agitation, abnormal movements, and sweating after amitriptyline was added.
An initial assessment attributed the presentation to psychogenic nonepileptic seizure. Persistent symptoms led to reassessment, including tremor, myoclonus, rigidity, sweating, and tachycardia. The authors diagnosed serotonin syndrome using the clinical features and medication history.
Medication presence is not mechanism
Triazolam’s presence in the regimen does not make the paper evidence that triazolam caused serotonin syndrome. The authors discuss the serotonergic actions of the other implicated drugs and the temporal relationship to the new addition.
Symptoms resolved after withdrawal of medications thought to be responsible and supportive care. Multiple changes and the lack of controlled rechallenge limit drug-by-drug causal separation. This remains a clinical case rather than proof of the risk associated with every similar prescription combination.
Why the distinction matters in toxicology
A complete medication list is necessary, but causal analysis also requires pharmacology and timing. Listing all drugs under a diagnosis can obscure which agents were suspected triggers, background treatments, or responses to illness.
The report supports reviewing recent additions when symptoms are initially attributed to psychiatric causes. It does not quantify the incidence of serotonin syndrome, establish a triazolam toxicity threshold, or provide a general test that distinguishes all seizure-like presentations. The particular clinical evidence should accompany the diagnostic label.
Source
Based on the supplied paper: Serotonin syndrome in a patient with chronic pain taking analgesic drugs mistaken for psychogenic no. PMC8688781.